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Objectives: To identify priority policy issues in access to medicines (ATM) relevant for low- and middle-income
countries, to identify research questions that would help address these policy issues, and to prioritize these research
questions in a health policy and systems research (HPSR) agenda.
Methods: The study involved i) country- and regional-level priority-setting exercises performed in 17 countries
across five regions, with a desk review of relevant grey and published literature combined with mapping and
interviews of national and regional stakeholders; ii) interviews with global-level stakeholders; iii) a scoping of
published literature; and iv) a consensus building exercise with global stakeholders which resulted in the
formulation and ranking of HPSR questions in the field of ATM.
Results: A list of 18 priority policy issues was established following analysis of country-, regional-, and global-level
exercises. Eighteen research questions were formulated during the global stakeholders’ meeting and ranked
according to four ranking criteria (innovation, impact on health and health systems, equity, and lack of research).
The top three research questions were: i) In risk protection schemes, which innovations and policies improve
equitable access to and appropriate use of medicines, sustainability of the insurance system, and financial impact
on the insured? ii) How can stakeholders use the information available in the system, e.g., price, availability, quality,
utilization, registration, procurement, in a transparent way towards improving access and use of medicines? and iii)
How do policies and other interventions into private markets, such as information, subsidies, price controls,
donation, regulatory mechanisms, promotion practices, etc., impact on access to and appropriate use of medicines?
Conclusions: Our HPSR agenda adopts a health systems perspective and will guide relevant, innovative research,
likely to bear an impact on health, health systems and equity.
Keywords: Access to medicines, Health systems, Health systems research, Priority settingBackground
The provision of reliable access to affordable, quality medi-
cines is a necessary component of functioning health
systems [1]. However, access to and use of essential
medicinesa is often poor in low- and middle-income
countries (LMICs), with particular challenges faced by the
poor. In the formal sector of LMICs, average availability of
medicines is 35% in public facilities and 66% in the private* Correspondence: bigdelim@who.int
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reproduction in any medium, provided the orsector, although prices are often unaffordable in the latter
[2]. Up to 50% of medicines are inappropriately prescribed
or dispensed and 50% are used incorrectly by patients [3].
Health-seeking behaviour towards an unregulated private
market is widespread [4,5]; substandard and counterfeit
medicines are also prominent [6-8]. Medicines typically ac-
count for 20% to 60% of health spending [2], and 50% to
90% of this amount is out-of-pocket [9].
There is a need to support Health Policy and Systems
Research (HPSR) in the field of medicines in resource
poor settings and the topic has been highlighted as an
important area of research by the Taskforce on HealthLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions in HPSR in LMICs showed 648 publications on
medicines between 2003 and 2009 [11]. This figure rep-
resents only 10% of global publications on medicines
and, of these, only 50% are written by authors from
LMICs.
Given limited resources available for HPSR in LMICs and
the large number of issues to be researched, priority setting
is an essential initial step to undertaking meaningful,
policy-relevant research. The World Report on Knowledge
for Better Health reports that policy-makers, researchers
and users are usually unaware of how research priorities
are set [12]; HPSR is often driven by donor support rather
than by country needs [13,14]. In relation to medicines,
priority-setting exercises have usually aimed at defining lists
of priority medicines to address global disease burden [15]
or specific health problems faced by vulnerable groups such
as mothers and children [16], but they have not defined a
HPSR agenda. The proceedings of the International Confer-
ence on Improving the Use of Medicines present key rec-
ommendations for research [17]. However, these are almost
100 research recommendations across 19 themes and are
not translated into prioritized research questions. Moreover,
as they emanate from the proceedings of a scientific confer-
ence, these recommendations reflect gaps in academic work
presented, which may not adequately reflect the concerns
of decisions-makers or patients and communities.
This paper presents a priority-setting exercise performed
by the Alliance for Health Policy and Systems Research
(AHPSR) between 2010 and 2012, with the objectives of: i)
identifying priority policy issues in access to medicines
(ATM) relevant for LMICs; ii) identifying research ques-
tions that would help address these policy issues; and iii)
prioritizing these research questions in an actionable HPSR
agenda.Stepwise approach to priority-setting for ATM
Step 1– Identify ATM policy  
concerns from key informant  
interviews





Country / regional reports
(Africa, Latin America and the 
Caribbean, Middle East and North 
Africa, South East Asia, Western
Pacific)
-   Literature review
-   Key informant interviews






Figure 1 Stepwise approach to priority-setting for access to medicineMethods
Analytical framework
The WHO framework “Equitable Access to Essential
Medicines: A Framework for Collective Action” [18] was
used as a guide. This framework presents four dimensions
of ATM: rational selection and use, affordable prices, sus-
tainable financing, and reliable health and supply systems.
Each of these four dimensions is influenced by determi-
nants of ATM rooted in local, national and international
context [19].
Stepwise approach
The stepwise approach used to determine research pri-
orities was adapted from Ranson et al. [20,21] and is
summarised in Figure 1. First, in 17 countries across five
regions, research teams performed an exhaustive litera-
ture review, focusing on ATM in their countries and
regions, and which covered published and grey literature
in local as well as international databases. This was
followed by key informant interviews (KIIs) and defin-
ition of priority policy issues. This resulted in a series of
country and regional reports, which were supplemented
by KIIs with global stakeholders. Second, a literature
scoping review was conducted to identify existing pub-
lished research, which was then mapped against the
priorities identified at country-, regional- and global-
level. The findings of the first two steps were shared
with a group of experts during a consultative workshop
aimed at formulating priority research questions and
ranking these in a prioritized HPSR agenda.
Country-, regional- and global-level priority setting
Seventeen countries were selected by the AHPSR based
on the following criteria: i) the capacity of in-country re-
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and iii) their ability to adopt a health system perspective
on ATM. Efforts were made to keep a balance between
regions and to include both low- and middle-income
countries. The analytical framework [18] was presented
and discussed in detail with research teams at an incep-
tion meeting. Meeting participants also discussed how
best to design and implement data collection tools that
would capture all elements of the framework and deter-
minants of access at all levels of the health system.
Country teams were given general directions for steps to
follow in collecting and analysing data. They were asked
to: i) perform a search of grey and published literature
related to their country and region, and identify existing
information on priority policy issues and existing re-
search in ATM; ii) map relevant stakeholders from vari-
ous groups: researchers, policy makers, health service
providers, civil society and NGOs including patient rep-
resentatives, donor agencies, pharmaceutical companies
and other relevant stakeholders; iii) select a sample of
stakeholders with adequate representation of all groups;
perform KIIs to identify priority policy issues and re-
search questions; iv) derive from these priority policy is-
sues on ATM and provide a list of research questions if
possible. Each team conceived search and survey
methods adapted to their contexts and in local lan-
guages. Table 1 presents the list of countries by region,
the number of informants in each country and whether
identification of priority policy issues was based onTable 1 Country-/regional-level approaches to priority setting
Region Country No. informan










South East Asia India 26
Western Pacific Cambodia NA*
Lao PDR 18
Vietnam 21
Eastern Mediterranean Iran 20
Pakistan 21
Lebanon 29
*The research team in Cambodia did not obtain authorization to conduct key inform
grey literature.consensus meeting vs. ranking (either in ranking meet-
ings or as a component of KIIs).
Institutions were requested to seek ethical approval in
their own country or region. Data collection took place
between November 2010 and December 2011 and coun-
try/regional reports were submitted to the AHPSR be-
tween May and December 2011b. The reports were read
by two reviewers independently (MB and JH). Priority
policy issues for each country were extracted and cate-
gorized according to the analytical framework. Results of
independent data extraction were compared; discrepan-
cies were discussed and resolved by returning to the
original report. Cross-cutting priority policy issues
appearing in at least three regions were identified and
considered as being of high priority. Priority policy
issues appearing in fewer than three regions were not
considered as high priority.
During the data extraction process, some amend-
ments were made to the original framework. The
team observed that there was considerable overlap be-
tween issues related to domains “affordable prices”
and “sustainable financing”. That is, when issues of
affordability as a demand-side aspect were studied,
naturally the supply-side, sustainable financing and
implications, were also studied and vice versa. Thus,
the two domains were merged into one, inclusive of
both demand- and supply-side financing. Further, the
domain “reliable health and supply system” covered a
large number of policy issues and was thereforets Method used to define priority policy issues
Ranking during face-to-face interviews or web-based surveys
Consensus meeting validating analysis of KII
Qualitative analysis of KIIs
NA*
Ranking during face-to-face interviews
Ranking during face-to-face interviews
Ranking meeting
Consensus meeting validating analysis of KII
Ranking meeting
ant interviews. Cambodia results are limited to desk review of published and
Table 2 Priority policy issues identified by country, region and global stakeholders’ interviews (unranked)
Priority policy issue No. of regions No. of global KII
1. Medicine selection and use
Generic medicines: perceptions of patients, communities, prescribers and dispensers of low quality and
efficacy of generic medicines. Inadequate demand for branded medicines, perceived as superior to generics.
5 15
Clinical practice guidelines, Standard Treatment Guidelines (STG), National Essential Medicines List (NEML):
development, implementation, enforcement, standardization of implementation between public and private
sector, procedures for addition and deletion to NEML, STG, formularies, generic policies. Impact of these on
medicines use and access.
5 15
Health seeking behaviour of patients, households and communities: knowledge and awareness of general
public on medicines, patients’ expectations from health services, adherence to prescribed medication and
treatment; self-medication.
5 14
Overuse of medicines: inappropriate use of injections, intravenous perfusions, antibiotics. 3 20
Financial and non-financial incentives for providers: impact of incentives on prescribing practices, quality of
care and access. Includes issues related to transparency of incentive systems or the impact of removing
financial link between patients and providers.
3 20
2. Sustainable financing and affordable prices
Medicines and health financing arrangements: coverage and reimbursement of medicines under pre-
payment and social health insurance schemes, impact on access, out-of-pocket and catastrophic
expenditures. Includes resource mobilization for universal coverage of medicines, fragmentation of financing
schemes, cost containment policies.
5 18
Resource allocation for health and medicines: government budget for health, funds allocated to health
service delivery and medicines. Includes issues related to accountability and disbursement of funds at
implementation level, and impact of these on medicine availability and prices.
5 18
Medicine pricing: pricing policies and regulations, and their impact on access, especially mark-up. Includes
issues related to transparency, corruption and speculation on medicine prices.
5 18
3. Leadership and governance
Crosscutting policies outside the health sector affecting health and medicines access: such as finance policies or
legal issues, coordination and engagement of stakeholders across sectors, and transparency (e.g., regulation and
management of conflicts of interest, regulation of incentives and profits above the health sector).
4 14
Governance over the private sector: mapping private sector health service delivery and assessment of
training and support needs, governance over the informal pharmaceutical markets, regulation of unethical
promotion practices and impact on access.
4 14
Donors’ agenda, funding type and funding mechanisms; impact on access. 3 18
4. Availability of medicines
Procurement, supply and stock management: limited capacity for these functions in resource limited
settings, including regulatory capacity and enforcement. Includes issues related to regulation and
enforcement of generic policy for procurement and supply.
5 9
Medicine availability in the public sector: comparison with availability in the private sector, consequences on
health seeking behaviour, medicine use, price and affordability.
4 9
Geographical accessibility: physical barriers, remoteness, geographical distribution of health services; impact
on access.
3 9
5. Human resources for health
Deployment/shortage and training of human resources for health, e.g., in underserved areas; impact on
access.
4 20
6. Quality of medicines and quality assurance systems
Counterfeit medicines: regional and national strategies, inspection and border control. 5 NA*
Substandard medicines: technical capacity for quality assurance in LMICs, e.g., laboratory capacity, minilabs;
regulation of quality standards and enforcement capacity.
4 16
7. Medicine information and information systems
Monitoring and evaluation systems on rational use, price and quality: data collection, flow of information,
adequate and timely use by all stakeholders.
3 5
*Global key informants who mentioned the issue of counterfeit often did mention that counterfeit medicines were symptoms of other problems in LMICs. A few
specifically recommended exercising caution and not limiting medicine quality to the issue of counterfeits and some said that the issue of substandard medicines
was more important.
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mains used were as follows:
1. Medicine selection and use
2. Sustainable financing and affordable prices of
medicines
3. Leadership and governance (reliable health and
supply systems)
4. Availability of medicines (reliable health and supply
systems)
5. Human resources for health (reliable health and
supply systems)
6. Quality of medicines and quality assurance systems
(reliable health and supply systems)Table 3 Literature scoping results




1. Medicine selection and use
Generic medicines 48
Clinical practice guidelines, Standard Treatment
Guidelines, National Essential Medicines Lists
49
Health seeking behaviour of patients, households
and communities
33
Overuse of medicines 34
Financial and non-financial incentives for providers 15
2. Sustainable financing and affordable prices
Medicine and health financing arrangements 27
Resource allocation for health and medicines 3
Medicine pricing 41
3. Leadership and governance
Cross-cutting policies above the health sector
affecting health and medicine access
12
Governance over the private sector 28
Donors agenda, funding type and funding mechanisms 14
4. Availability of medicines
Procurement, supply and stock management 12
Medicine availability in the public sector 29
Geographical accessibility 16
5. Human resources for health
Deployment/shortage and training of human
resources for health
3
6. Quality of medicines and quality assurance systems
Counterfeit medicines 9
Substandard medicines 34
7. Medicine information and information systems
Monitoring and evaluation systems on rational use,
price and quality
35
aSystematic reviews.7. Medicines information and information systems
(reliable health and supply systems)
To collect data on priority policy issues from a global
perspective, 23 stakeholders from headquarters and
regional offices, of international multilateral and bilateral
agencies, academia and NGOs were interviewed. These
informants were selected for their expertise and know-
ledge of ATM issues at international level. Priority policy
issues identified at country- and regional-levelc were
used to design a semi-structured telephone interview
guide. In relation to each of the seven domains of the
revised framework and through a series of open-ended





Quantitative Qualitative Mixed Other
6 1 (1) 8 23 13 3
12 4 (4) 8 17 17 3
2 1 (3) 2 14 11 3
4 2 (2) 11 12 7 2
6 1 (4) 0 5 4 2
12 1 (4) 10 3 10 0
1 0 (0) 1 00 1 1
12 0 (3) 19 0 9 10
1 1 (1) 0 1 3 7
4 1 (2) 4 14 2 6
10 0 (0) 4 3 3
2 0 (0) 5 4 3 0
5 1 (2) 6 4 14 3
8 1 (1) 5 4 4 2
2 0 (0) 0 1 2 0
2 3 (3) 1 1 2 2
9 1 (1) 8 12 5 8
4 1 (1) 4 11 8 11
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level, and whether any issue was missing and would
deserve to be prioritized. Interviews were performed be-
tween June and November 2011 by researchers external
to the AHPSR with 23 informants who responded in
their professional capacity. Interviews were conducted in
English following email agreement and oral consent at
the start of the interview. Interviews were not recorded
but transcribed; transcripts were sent back to the inter-
viewees for final agreement. Transcripts were read by
two independent readers (JH, who performed the inter-
views and DJ, who did not) and priority policy issues
identified by global key informants were extracted in an
Excel spread sheet, according to the modified analytical
framework. Results of independent reviews were com-
pared and discrepancies were discussed and resolved by
returning to the original transcripts.
Policy issues were categorized according to the seven
domains above. Topics were ordered firstly according to
the number of regions in which the issue was raised and
second according to the number of interviewees who
raised the issue at global level.
Literature scoping
Using the list of priorities identified through the KIIs
and the country reports, a search strategy was devised to
extract relevant literature. The search strategy was
adapted from a review recently published by the AHPSR
[11] and is presented in Additional file 1 and described
below. As PubMed is limited in its inclusion of relevant
LMIC literature, additional sources were considered.
Country and regional teams conducted literature reviews
on ATM in their local context, using international and
local databases, resulting in a comprehensive reference
list for each country and region. To supplement the
global search, reference lists provided by country and
regional teams were included to strengthen the inclu-
siveness of the literature scoping (see Additional file 2
for the list of databases searched by country, regional
and global research teams). Finally, a report by Gray and
Suleman as commissioned by the AHPSR was used as
well to further broaden the search [22]. These additional
sources covered major databases for published and grey
literature and databases specific to LMICs. From these,
relevant publications and systematic reviews were in-
cluded in the scoping exercise.
Literature search strategy
The main search theme included three concepts: medi-
cines, LMICs, and access. These were combined with
specific search terms related to each of the seven do-
mains of the analytical framework. The global search
was limited to PubMed 2003–2012 with additional refer-
ences being drawn from country literature reviewsthrough local and global databases highlighted in
Additional file 2. Published papers were screened by two
independent researchers and were included based on
whether or not they were relevant to access to medi-
cines, set in LMICs, and relevant to the priority areas.
Results focusing on vaccines, research and development,
legislative details of intellectual property rights, and
pharmacoepidemiology were excluded as they were not
outlined as priority ATM concerns at this time. Ab-
stracts of included articles were also reviewed by two
independent researchers and the following information
was extracted for each publication: country; region;
urban vs. rural setting focus; level at which the study
was conducted, according to the same levels as previ-
ously outlined, namely i) patient, household, community,
ii) health service delivery, health service provider, iii)
health sector, iv) cross-cutting national policies, and v)
international level; public vs. private sector focus; study
methods: qualitative, quantitative, mixed, systematic re-
view, other (including reviews and commentaries);
whether the study presents impact or results of an inter-
vention aimed at improving access to medicines; and
which of the 18 policy issues was addressed in the
article. Where studies were focused on more than one
setting or more than one of the seven priority domains,
this has been outlined.
Formulation of research questions and ranking
A global stakeholders meeting was organized in Bangkok
on 6–8 March 2012. Participants from academia were
selected based on their records of research and publica-
tions in the field of pharmaceuticals and health systems.
Non-academia participants were selected to represent
decision makers in the public and private sectors, which
included multi-lateral agencies, government agencies,
NGOs, pharmaceutical companies, and private founda-
tions. The 20 participants included three who lead
country-level exercises and five who were interviewed as
part of the global stakeholders’ interviews. Participation
was voluntary and based on availability. In preparation
for the meeting, participants received summaries of indi-
vidual country- and regional-level priority setting exer-
cises, a background paper detailing the methods and
results of country-, regional- and global-level priority
setting as well as methods and results of literature scop-
ing, and a spreadsheet presenting the full list of refer-
ences including abstracts. During the first half of the
meeting, 14 participants from academia reviewed the list
of priority policy issues resulting from country-,
regional-, and global-level research; and agreed on the
categories as well as the wording. Once agreement was
reached, they formulated research questions correspond-
ing to each of the ATM policy issues identified in the
first two steps. This exclusive time for formulation of
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culty of translating policy issues into health policy and
systems research questions, which required the expertise
of researchers. During the second half of the meeting,
non-academic participants joined the group, reviewed
the list of policy issues, and drafted questions formulated
by academia. Consensus was reached on a final set of 18
unranked research questions.
Participants also debated and reached consensus on
four ranking criteria, to which they decided to attribute
the same weight:
1. Innovation: Will the research stimulate innovation?
2. Impact: Is the resulting research likely to be effective
in strengthening health systems and improving
health?
3. Equity: Is the research likely to reduce disparities in
health outcomes, perceived as unfair?
4. Lack of research: Is there a lack of research on this
topic?
In addition, participants suggested and agreed to add
an overall score, irrespective of ranking criteria, that
would assess the overall importance of each research
question in LMICs and proposed that each participant
lists his/her top five priority research questions at the
end of the questionnaire. The questionnaire was modi-
fied to account for these suggestions.
Participants ranked the 18 research questions through
an individual anonymous questionnaire. A five-point
Likert scale was used for each ranking criteria where one
represented low priority and five represented high prior-
ity. Three different methods were used for combining
scores across participants:
– First, the “total score” involved: i) for each
participant and question, summing the four ranking
criteria (given the consensus decision to assign equal
weight to each criterion); and ii) taking the flat
(non-weighted) average of scores for each question
across all participants. Questions were ranked from
one (top rank, highest average total score) to 18
(lower rank, lowest average total score).
– Second, the “overall score” was entered also using a
five-point Likert scale where one represented a low
overall priority and five represented a high overall
priority. The overall score was also combined by
taking a flat average for each question, across all
participants. Questions were ranked from one (top
rank, highest average overall score) to 18 (lower
rank, lowest average overall score).
– Third, the “top five” was a simple count of the
number of times each research question was listed
in the top five priorities of all participants andquestions were ranked from one (highest number of
counts) to 18 (lowest number of counts).
The results of the ranking exercise were analysed on
site, presented and discussed in plenary, and consensus
was reached on top priority questions.Results
Policy concerns raised at country-, regional-, and
global-level
A total of 26 crosscutting high priority policy issues were
identified at country- and regional-level. Nine policy is-
sues were consistently raised in all five regions and re-
lated to: i) perception of generic medicines by patients,
prescribers and providers, and their preference for
branded medicines; ii) knowledge, awareness, and health
seeking behaviour of patients; iii) development of central
and essential policy documents such as standard treat-
ment guidelines and national essential medicine lists; iv)
universal coverage, social health protection and coverage
of medicines under health financing arrangements; v)
level of public and government funding for health and
medicines; vi) inefficiencies in budget disbursement and
implementation; vii) medicine pricing policies; viii) cap-
acity of staff and systems for procurement, supply and
stock management; and ix) fight against counterfeit
medicines. An additional eleven issues were raised in
four regions and six issues were raised in three regions.
Policy issues raised by less than three regions are consid-
ered as low priority and are not presented here.
A total of 23 informants were interviewed at global
level, of which six were women. Ten informants origi-
nated from a LMIC. Interviewees had expertise either in
pharmaceuticals or health systems and worked at head-
quarters of international multilateral agencies (n = 8), at
regional offices of multilateral agencies (n = 4), in a bi-
lateral donor organization (n = 1), in international
NGOs (n = 4) and six were researchers in academic in-
stitutions. The results of global KIIs were fairly consist-
ent with country- and regional-level results. Global KIIs
placed more emphasis on the role of human resources
for health in medicine access, although for both groups,
the specific policy focus was the impact of financial and
non-financial providers’ incentives on access. The sec-
ond most important domain for global key informants
was the same as for countries and regions: sustainable
financing and affordable prices. Consistent with data
from countries and regions, quality issues came third
with global key informants; however, here, a focus on
substandard medicines was considered to be more crit-
ical than counterfeit medicines as these were seen as a
symptom of other system failures outside of quality as-
surance. In general, all priority policy issues that were







Innovation Impact Equity Lack of
research
1. In risk protection schemes, which innovations and policies improve equitable
access to and appropriate use of medicines, sustainability of the insurance system,
and financial impact on insurance members?
1 1 1 2 1 2 1
2. What are the impacts of different resource allocation mechanisms in fragmented
or decentralized health or pharmaceutical systems on access to and use of
medicines?
11 11 14 15 14 8 10
3. What are the impacts of different pricing policies and strategies on medicine
prices, availability and use?
6 3 8 10 11 3 3
4. What is the impact of different strategies on perception and use of quality
assured low-cost generic medicines by key stakeholders including patients,
prescribers, dispensers, regulators?
10 10 10 11 10 10 12
5. What is the impact of individual or combined strategies, in particular regulation
and economic incentives, in implementing Standard Treatment Guidelines or
Essential Medicines list, on appropriate use of medicines in the public and private
sector?
15 14 12 16 15 14 15
6. Which innovative strategies targeting individuals, households, communities and
systems improve appropriate demand (health seeking behaviour) for access and
use of essential medicines?
4 8 4 3 4 5 6
7. What are the best ways of optimizing supply chain management and improving
transparency using a systems perspective to improve access to medicines?
16 17 17 12 16 17 16
8. What is the effectiveness and cost-effectiveness of interventions that can be
used to detect and reduce supply and demand of counterfeit (fake/falsified)
medicines?
13 15 12 9 13 16 9
9. How do we understand and intervene in labour markets for pharmaceuticals to
improve the quality of and access to essential medicines?
12 13 16 14 9 13 7
10. What are effective strategies to reduce substandard medicine production, to
improve medicine quality and regularly disseminate results?
14 12 11 12 12 15 12
11. How do non-health sector policies (e.g., industry, trade and intellectual
property, legal and constitutional, civil service, transport, banking, education,
defence, financial systems, customs) influence access to and use of medicines?
5 6 4 4 4 5 4
12. How do policies and other interventions into private markets (such as
information, subsidies, price controls, donation, regulatory mechanisms, promotion
practices, etc.) impact on access to and appropriate use of medicines?
2 2 4 1 3 4 2
13. What are the lessons learned from best practices for public sector management
of essential medicine programs to improve access and appropriate use of
medicines?
17 15 17 18 17 12 17
14. Based on evidence of impact of inappropriate drug use on burden of disease,
drug resistance and systems and household expenditures, how can systems most
effectively and sustainably scale up interventions?
9 8 8 4 4 9 10
15. What incentives in a health system optimize prescribing, dispensing and sales
practices among the full range of providers (public, private, formal and informal)?
8 4 3 4 4 7 7
16. What are the best practices of donor and NGO behaviour in working with
stakeholders, to strengthen capacity of national systems to improve access to and
appropriate use of medicines?
18 18 14 17 18 18 18
17. Which innovations effectively improve access (including geographic
accessibility, social acceptability, availability, and financial accessibility) of under-
served communities to essential medicines, including community engagement
strategies?
3 7 7 8 8 1 12
18. How can stakeholders use the information available in the system (e.g., price,
availability, quality, utilization, registration, procurement) in a transparent way
towards improving access and use of medicines?
7 4 2 4 2 10 4
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as important concerns for global key informants.
A consolidation of results from country, regional, and
global exercises allowed authors to define a final list of18 crosscutting high-priority policy issues related to
ATM in LMICs. Inclusion of priority policy issues in this
list was based first on the number of regions where the
issue was raised and second according to the number of
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of Global KII were consistent with country- and
regional-level results, no additional policy issues raised
by Global Key Informants were added to the list of
country and regional priorities. A few policy issues
among the list of 26 priorities resulting from country-
and regional-level exercises were combined as they
appeared redundant or strongly linked (e.g., “provider
payment methods and financial incentives to providers”
was combined with “financial and non-financial incen-
tives to providers”; “procurement and supply of generic
medicines” was combined with “quality of generic
medicines”).
Literature scoping
A total of 1,279 articles were retrieved from PubMed;
619 were found relevant for our study. Results show a
distribution of publications predominantly in Sub-
Saharan Africa (32.1%), followed closely by the Asian
continent (23.6%, with 12.6% in South Asia and 11% in
East Asia and the Pacific), and Latin America and the
Caribbean (18.6%). A majority of publications focused
on the public sector (65.4%) followed by both public and
private sector (8.7%); 15.8% of publications studied only
the private sector. Half of the publications had a specific
urban focus and 12% specifically targeted rural settings.
From reference lists of country and regional priority-
setting reports, an additional 72 articles were identified
as relevant to the search. Sixteen systematic reviews
were also extracted from the review by Gray and
Suleman [22]. A total of 707 references were categorized,
based on screening through each article, according to
the list of priority policy issues in ATM (Table 3).
Priority policy issues for which there are fewer refer-
ences in the literature include resources allocation for
health and medicines; deployment and shortage of
human resources for health; counterfeit medicines;
procurement, supply and stock management; and cross-
cutting policies outside the health sector affecting health
and medicines. Moreover, some of the priorities are only
covered by less robust research methodologies. For ex-
ample, for the following five priorities, no publication
was identified that attempts to assess the effects or out-
comes of specific interventions: resource allocation for
health and medicines; health seeking behaviour of pa-
tients, households and communities; crosscutting pol-
icies outside the health sector affecting health and
medicines; governance over the private sector and finan-
cial and non-financial incentives for providers.
Formulation of research questions and ranking
Fourteen academic researchers were present during the
first half of the meeting, including one private founda-
tion and three researchers who had performed country-and regional-level priority setting exercises. They came
from institutions in Brazil, China, Ghana, Iran, Mexico,
South Africa, Switzerland, Sweden, Thailand, and the
United States of America. Seven stakeholders joined the
academic group during the second half of the meeting;
they came from international multilateral agencies
(n = 2), a government agency (n = 1), NGOs (n = 2), a
pharmaceutical company (n = 1), and a private founda-
tion (n = 1). Two WHO officers were also present. Eight
participants were female. Research questions addressing
the 18 priority policy issues were formulated by the aca-
demic researchers, and then reviewed by the second
group of stakeholders who introduced minor editorial
revisions. While the experts did have the option of de-
veloping more than one research question per issue, they
jointly decided on a single question corresponding to
each policy issue. Table 4 presents the research ques-
tions formulated by the group and the results of the
ranking exercise according to the three ranking methods.
It also disaggregates the results according to the four
ranking criteria (Innovation, Impact, Equity, and Lack of
Research).
Participants in the ranking exercise were presented
with preliminary quantitative analyses of all three rank-
ing methods. They reached a consensus that priority
should be given to research questions 1, 12 and 18.
Question 1 (“In risk protection schemes, which innova-
tions and policies improve equitable access to and appro-
priate use of medicines, sustainability of the insurance
system, and financial impact on insurance members?”)
was overwhelmingly ranked as a top priority, irrespective
of the ranking method used. This question also scored
as a high priority according to all ranking criteria (top
priority with regards to Impact and Lack of Research,
second priority with regards to Innovation and Equity).
This research topic corresponds to a priority policy issue
raised consistently in all five regions and by 18 out of 23
global key informants (Table 2). As confirmed by our
literature scoping, medicine publications have only re-
cently shifted towards examining health-financing ar-
rangements and investigating medicine prices in LMICs.
Our priority setting exercise confirms an on-going inter-
est in these topics, which are also consistent with the
current trend of focussing on universal coverage in a
post-Millennium Development Goal world.
The top five ranking method placed Question 18
(“How can stakeholders use the information available in
the system, e.g., price, availability, quality, utilization,
registration, and procurement, in a transparent way to-
wards improving access and use of medicines?”) in sec-
ond position while the results of the total score and
overall score methods pointed to Question 12 (“How do
policies and other interventions into private markets
(such as information, subsidies, price controls, donation,
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on access to and appropriate use of medicines?) as a sec-
ond priority. Question 12 was considered highly innova-
tive and addressing a substantial research gap, as
confirmed by our literature scoping. Question 18, related
to medicine information, was regarded as potentially
achieving high impact.
Consensus was reached among the meeting partici-
pants for the above top three ranking research questions
that needed attention and investment in the future. Par-
ticipants suggested that the results of the ranking,
disaggregated by ranking criteria, be made publicly avail-
able to allow researchers, decision makers and funders
to select research questions according to their expertise
and their needs, depending on whether they wanted to
focus on equity, innovation, impact on health and health
systems or on filling existing research gaps.
Discussion
A list of 18 research questions corresponding to policy
issues in ATM raised at country-, regional-, and global-
level were thoroughly formulated and ranked during our
priority-setting exercise. The prioritized HPSR agenda in
ATM corresponds to existing research gaps and sets the
tone for future research that is likely to be innovative
and to have a higher impact on health, health systems,
and equity. The top ranking research questions relate to
medicine financing (“In risk protection schemes, which
innovations and policies improve equitable access to and
appropriate use of medicines, sustainability of the insur-
ance system, and financial impact on insurance mem-
bers?”); medicine information and information systems
(“How can stakeholders use the information available in
the system, e.g., price, availability, quality, utilization,
registration, and procurement, in a transparent way to-
wards improving access and use of medicines?”); and to
leadership and governance, and more specifically, stew-
ardship over the private sector (“How do policies and
other interventions into private markets (such as infor-
mation, subsidies, price controls, donation, regulatory
mechanisms, promotion practices, etc.) impact on access
to and appropriate use of medicines?). This priority-
setting approach has been successful in ensuring that a
health systems lens is adopted in ATM research [19]: the
top priority research questions are tightly interlinked
with three other building blocks of the health system,
namely health financing, health information systems and
governance [1]. Moreover, all three research questions
are related to the building block of service delivery. The
other research questions highlight the importance of in-
centives in the health system, demand-side and equity
aspects, and contextual factors outside the health sector.
Viergever et al. have established a checklist of nine
common themes of good practice for health researchpriority setting [23]. Our priority-setting exercise was
assessed against this checklist as follows:
1. Context: This priority-setting exercise was the major
activity of the inception phase for the ATM project
launched by the AHPSR in 2010 (www.who.int/
alliance-hpsr). The objectives of the project are to
increase availability and use of HPSR evidence in the
field of ATM, and thereby improve access for the
most vulnerable populations in LMICs. Adequate
level of funding and human resources were provided
by the AHPSR since the start of the project and it
was foreseen that a bottom-up exercise would be
conducted in select countries to generate context-
specific evidence on policy issues and priority
research questions.
2. Stepwise comprehensive approach: We adopted a
stepwise approach, similar to previous priority-
setting exercises conducted by the AHPSR. This is
consistent with the approach used by Ranson and
Bennett [13], who conclude that more successful
approaches for considering HPSR priority-setting are
country-driven, interpretive and include a wide
range of stakeholders. Consistent with this, the
Taskforce on Health Systems Research [10] also puts
forward approaches to setting priorities in HPSR,
based on consensus views of informed participants.
3. Inclusiveness: Our study starts with a bottom-up,
country-driven approach and all prioritised research
questions respond to policy issues in ATM raised by
countries and regions. We have also paid particular
attention to the inclusion of typically neglected, but
significant actors such as the pharmaceutical
industry.
4. Information gathering: Data collection at country-,
regional-, and global-level included KIIs on priority
policy issues in ATM as well as a comprehensive
literature scoping.
5. Plans to translate priorities into research: From the
start, it was known that the AHPSR had available
funding for a call for research proposals based on
established HPSR agenda (http://www.who.int/
alliance-hpsr/alliancehpsr_atmcall_for_eoi.pdf )d.
6. Criteria: In all priority-setting exercises, whether for
health interventions, health research, or HPSR,
authors insist on the importance of criteria used for
ranking [24-29]. The four criteria we used for our
priority-setting are considered as relevant in many
of the above publications: equity is a common
criterion to almost all priority-setting papers above,
the expected impact of research on health and
health systems is considered by several authors as
well as lack of existing and previous research
[20,21,24]. Innovation is seldom used by other
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research questions ranked in their study on health
financing were usually not very innovative [20];
introducing innovation as a criteria helps to
overcome this specific weakness of previous AHPSR
priority-setting exercises. Ranson et al. [20,21]
concur with COHRED [24] that ranking criteria
should be based on consensus among participants
and this is especially relevant for HPSR [13]. We
have applied this by discussing and adjusting ranking
criteria prior to conducting the ranking exercise;
stakeholders suggested two alternate ranking
methods (overall score and top five list) which were
used to discuss the final prioritized agenda.
7. Methods: Viergever et al. [23] suggest that priority-
setting methods may be consultative-based, metrics-
based, or a combination of both, while the Taskforce
on Health Systems Research [10] and Ranson and
Bennett [13] support the use of qualitative methods
to prioritize HPSR agendas. Our method was a
mixed approach, combining qualitative data
collected at country-, regional-, and global-level, a
consensus-based approach to formulating the final
research questions, a metrics-based approach to the
ranking exercise, and finally, consensus-building
towards the final agenda.
8. Transparency: The entire process has been
transparent with each step having been documented
starting with country- and regional-level reports and
ending with a full research report following the
ranking workshop.
9. Evaluation: The process has not yet undergone any
formal evaluation, but is assessed against the
checklist of nine common themes of good practice
for health research priority-setting as established by
Viegever et al. [23].
Particular attention has been devoted to mitigating
some of the weaknesses of prior priority-setting exer-
cises [20,21]. The lack of standardized methodology for
country- and regional-level exercises is one such limita-
tion. To address this, some level of standardization was
introduced by holding an inception meeting prior to
field data collection (Cambodia, October 2010). Exten-
sive discussions took place to understand the analytical
framework, identify determinants of ATM at local, na-
tional and international levels that should guide the data
collection process and map stakeholders. However, no
further standardization was introduced beyond the con-
ceptual level in order to provide sufficient flexibility for
the development of context-specific methodologies, in
particular with regard to survey tools. In previous exer-
cises, it was documented that key informants had diffi-
culty formulating research questions, and felt morecomfortable discussing policy issues. In response to this
limitation, exclusive time has been devoted to formula-
tion of research questions by experienced academic
researchers during the consultation and ranking work-
shop. On the other hand, using the expertise of aca-
demic experts gathered in a global meeting to formulate
research questions may bias the questions towards
global level research priorities; however, the presence of
researchers from LMICs in the meeting, especially lead
country and regional investigators, mitigated such biase.
Another limitation of the formulation of research ques-
tions was that an in-depth triangulation of research pri-
orities with existing research could not take place;
instead academic experts referred to a scoping of the lit-
erature, with limited consideration of quality of pub-
lished papers. This was combined with their own
knowledge of available research in the field.
As in any other exercise of this kind, the choice of the
frameworks guides the way in which policy concerns are
voiced during KIIs. The WHO framework [18] is largely
centred on health sector level issues. Such limitation was
mitigated by the stepwise comprehensive and inclusive
approach adopted for data collection, especially mapping
and inclusion of stakeholders at country-, regional-, and
global-level.
An intermediate result of our research consists of 17
country-level priority-setting exercises that can be used
by national decision-makers to identify important gaps
in their pharmaceutical policies and programmes. Sum-
maries of country- and regional-level results are avail-
able on the AHPSR website and country research teams
pursue their efforts of disseminating these results in na-
tional and international level, including in peer-reviewed
publications [30-32]. Further, the proposed prioritized
HPSR agenda in ATM comprises 18 priority research
questions, of which only three have been selected as top
priority for the AHPSR Call for Expressions of Interest.
Obviously, this investment is limited. Academic institu-
tions at national and international level as well as
funding agencies may use this research agenda to orient
their efforts and investments towards policy-relevant
research in ATM. Being a step-wise priority-setting
process, inclusive of a range of stakeholders, including
donors, this exercise serves to support policy-relevant
research by demonstrating the need and desire for it
across stakeholders and by bringing together those inter-
ested in the field, leading to improved consolidation of
both research and policy-making efforts. Several agen-
cies present at the Global Stakeholders Meeting have
already expressed willingness to support this research
agenda.
The authors hope that this paper will contribute to the
overall science – both in terms of methodological
approaches and findings – of priority setting for
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much remains to be done in strengthening the field of
priority-setting. First, many organizations funding health
or development research require broader lists of prior-
ities as they may need to allocate research across sectors
or broadly within the health sector. A broad, cross-
sectoral priority-setting exercise might be particularly
relevant as the international community establishes –
and identifies strategies for addressing – the post-2015
development goals [33]. Second, in order for national-
level policy-makers to decide how to spend scarce re-
search resources, priority-setting exercises may need to
be carried out at the country-level. This requires a com-
mitment to both building up the skills for conducting
priority-setting exercises, and using their results. Rela-
tively few LMICs regularly conduct priority-setting exer-
cises for health research (the most cited examples being
Malaysia and Brazil). Third, priority-setting exercises at
global level tend to look at demand for, and supply of,
research evidence at a single point in time. In fact, the
issues of greatest priority to policy-makers and the cor-
responding evidence base are fast changing. This calls
for priority-setting processes that are dynamic (“real-
time”), or at least revised at regular intervals.
Conclusions
The priority-setting process described in our paper
established a HPSR agenda in ATM, with 18 prioritized
and thoroughly formulated research questions. The top-
priority questions focused on: i) medicine financing within
risk protection schemes; ii) medicine information; and iii)
interventions into private markets. The agenda adopts a
health systems perspective and will guide innovative
research likely to bear a higher impact on health, health sys-
tems, and equity.
Endnotes
aAccording to the WHO, “Essential medicines are
those that satisfy the priority health care needs of the
population. They are selected with due regard to public
health relevance, evidence on efficacy and safety,
and comparative cost-effectiveness.” [http://www.who.
int/topics/essential_medicines/en/] Accessed 3 March
2013.
bSummaries of country- and regional-level priority set-
ting exercises can be found at the following link [http://
www.who.int/alliance-hpsr/projects/medicines/en/index.
html].
cThis excluded Rwanda and Ghana which started later
than other countries and had not submitted their draft
report when the global-level interviews were designed.
dAccessed 18 January 2013.
eIt should be noted that lead country and regional
investigators did not participate in the ranking exercise.Additional files
Additional file 1: Literature scoping: search strategy.
Additional file 2: Databases searched by country, regional and
global research teams.
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